Search

Your search keyword '"Massaro, Fulvio"' showing total 129 results
Start Over "Massaro, Fulvio"
129 results on '"Massaro, Fulvio"'

1. Diagnosis and treatment of Chiari malformation and syringomyelia in adults: international consensus document

Author

Ciaramitaro, Palma, Massimi, Luca, Bertuccio, Alessandro, Solari, Alessandra, Farinotti, Mariangela, Peretta, Paola, Saletti, Veronica, Chiapparini, Luisa, Barbanera, Andrea, Garbossa, Diego, Bolognese, Paolo, Brodbelt, Andrew, Celada, Carlo, Cocito, Dario, Curone, Marcella, Devigili, Grazia, Erbetta, Alessandra, Ferraris, Marilena, Furlanetto, Marika, Gilanton, Mado, Jallo, George, Karadjova, Marieta, Klekamp, Jorg, Massaro, Fulvio, Morar, Sylvia, Parker, Fabrice, Perrini, Paolo, Poca, Maria Antonia, Sahuquillo, Juan, Stoodley, Marcus, Talamonti, Giuseppe, Triulzi, Fabio, Valentini, Maria Consuelo, Visocchi, Massimiliano, and Valentini, Laura

Published
2022
Full Text
View/download PDF

2. Beyond Chemotherapy: Present and Future Perspectives in the Treatment of Lymphoproliferative Disorders.

Author

Massaro, Fulvio, Andreozzi, Fabio, Abrassart, Tom, Castiaux, Julie, Massa, Hanne, Rizzo, Ornella, and Vercruyssen, Marie

Subjects
LYMPHOPROLIFERATIVE disorders, BISPECIFIC antibodies, HODGKIN'S disease, CHIMERIC antigen receptors, HEMATOLOGIC malignancies
Abstract

Over the past three decades, the treatment of lymphoproliferative disorders has undergone profound changes, notably due to the increasing availability of innovative therapies with the potential to redefine clinical management paradigms. A major impact is related to the development of monoclonal antibodies, checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T (CAR-T) cell therapies. This review discusses the current landscape of clinical trials targeting various hematological malignancies, highlighting promising early-phase results and strategies to overcome resistance. Lymphoproliferative disorders encompass a range of conditions: while in Hodgkin lymphoma (HL) the goal is to reduce chemotherapy-related toxicity by integrating immunotherapy into the frontline setting, peripheral T cell lymphoma (PTCL) lacks effective targeted therapies. The review emphasizes a shifting therapeutic landscape towards precision medicine and treatment modalities that are less toxic yet more effective. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Correction to: Diagnosis and treatment of Chiari Malformation and syringomyelia in adults: International Consensus Document

Author

Ciaramitaro, Palma, Massimi, Luca, Bertuccio, Alessandro, Solari, Alessandra, Farinotti, Mariangela, Peretta, Paola, Saletti, Veronica, Chiapparini, Luisa, Barbanera, Andrea, Garbossa, Diego, Bolognese, Paolo, Brodbelt, Andrew, Celada, Carlo, Cocito, Dario, Curone, Marcella, Devigili, Grazia, Erbetta, Alessandra, Ferraris, Marilena, Furlanetto, Marika, Gilanton, Mado, Jallo, George, Karadjova, Marieta, Klekamp, Jorg, Massaro, Fulvio, Morar, Sylvia, Parker, Fabrice, Perrini, Paolo, Poca, Maria Antonia, Sahuquillo, Juan, Stoodley, Marcus, Talamonti, Giuseppe, Triulzi, Fabio, Valentini, Maria Consuelo, Visocchi, Massimiliano, and Valentini, Laura

Published
2022
Full Text
View/download PDF

11. HIGHLIGHTS FROM THE 20TH IWCLL

Author

Massaro, Fulvio, De Wilde, Virginie, Massaro, Fulvio, and De Wilde, Virginie

Abstract

info:eu-repo/semantics/published

Published
2023

13. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN

Author

Breccia, Massimo, Andriani, Alessandro, Montanaro, Marco, Abruzzese, Elisabetta, Buccisano, Francesco, Cedrone, Michele, Centra, Antonietta, Villivà, Nicoletta, Celesti, Francesca, Trawinska, Malgorzata Monica, Massaro, Fulvio, Di Veroli, Ambra, Anaclerico, Barbara, Colafigli, Gioia, Molica, Matteo, Spadea, Antonio, Petriccione, Luca, Cimino, Giuseppe, and Latagliata, Roberto

Published
2017
Full Text
View/download PDF

14. Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC)

Author

Morano, Salvatore Giacomo, Latagliata, Roberto, Girmenia, Corrado, Massaro, Fulvio, Berneschi, Paola, Guerriero, Alfonso, Giampaoletti, Massimo, Sammarco, Arianna, Annechini, Giorgia, Fama, Angelo, Di Rocco, Alice, Chistolini, Antonio, Micozzi, Alessandra, Molica, Matteo, Barberi, Walter, Minotti, Clara, Brunetti, Gregorio Antonio, Breccia, Massimo, Cartoni, Claudio, Capria, Saveria, Rosa, Giovanni, Alimena, Giuliana, and Foà, Robin

Published
2015
Full Text
View/download PDF

15. New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy

Author

Andreozzi, Fabio, Massaro, Fulvio, Wittnebel, Sebastian, Spilleboudt, Chloé, Lewalle, Philippe, Salaroli, Adriano, Andreozzi, Fabio, Massaro, Fulvio, Wittnebel, Sebastian, Spilleboudt, Chloé, Lewalle, Philippe, and Salaroli, Adriano

Abstract

For decades, intensive chemotherapy (IC) has been considered the best therapeutic option for treating acute myeloid leukemia (AML), with no curative option available for patients who are not eligible for IC or who have had failed IC. Over the last few years, several new drugs have enriched the therapeutic arsenal of AML treatment for both fit and unfit patients, raising new opportunities but also new challenges. These include the already approved venetoclax, the IDH1/2 inhibitors enasidenib and ivosidenib, gemtuzumab ozogamicin, the liposomal daunorubicin/cytarabine formulation CPX-351, and oral azacitidine. Venetoclax, an anti BCL2- inhibitor, in combination with hypomethylating agents (HMAs), has markedly improved the management of unfit and elderly patients from the perspective of improved quality of life and better survival. Venetoclax is currently under investigation in combination with other old and new drugs in early phase trials. Recently developed drugs with different mechanisms of action and new technologies that have already been investigated in other settings (BiTE and CAR-T cells) are currently being explored in AML, and ongoing trials should determine promising agents, more synergic combinations, and better treatment strategies. Access to new drugs and inclusion in clinical trials should be strongly encouraged to provide scientific evidence and to define the future standard of treatment in AML., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2022

16. Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis

Author

Massaro, Fulvio, Meuleman, Nathalie, Bron, Dominique, Vercruyssen, Marie, Maerevoet, Marie, Massaro, Fulvio, Meuleman, Nathalie, Bron, Dominique, Vercruyssen, Marie, and Maerevoet, Marie

Abstract

Classical Hodgkin lymphoma (HL) patients presenting a relapsed/refractory (R/R) disease are currently managed with salvage chemotherapy followed by autologous stem cell transplantation (ASCT). However, almost 25–30% of these patients fail to achieve a complete response (CR) with standard salvage regimens. In this retrospective study, we evaluated the efficacy of a combination of brentuximab vedotin (BV) and pembrolizumab in a series of HL patients presenting with a high-risk, multi-refractory disease. Patients achieving a Deauville score ≤4 proceeded to ASCT consolidation. After ASCT, patients received BV as maintenance for a total of 16 administrations. We collected data from 10 patients with a median age of 30.7 years. At a median follow-up of 16.5 months, we reported a complete metabolic remission (CMR) in eight patients (80%), with seven patients (70%) directly proceeding to ASCT (the other two patients in CMR are still undergoing treatment). BV consolidation was started in six patients and completed by three patients (one ongoing, two interruption). Two patients (20%) presented a progressive disease (PD) and subsequently died, while the others are still in CMR. The BV and pembrolizumab combination is a very effective bridge treatment to ASCT for high-risk R/R HL patients., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2022

20. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real‐life experience

Author

Massaro, Fulvio, primary, Pavone, Vincenzo, additional, Stefani, Piero Maria, additional, Botto, Barbara, additional, Pulsoni, Alessandro, additional, Patti, Caterina, additional, Cantonetti, Maria, additional, Visentin, Andrea, additional, Scalzulli, Potito Rosario, additional, Rossi, Andrea, additional, Galimberti, Sara, additional, Cimminiello, Michele, additional, Gini, Guido, additional, Musso, Maurizio, additional, Sorio, Marco, additional, Arcari, Annalisa, additional, Zilioli, Vittorio Ruggero, additional, Luppi, Mario, additional, Mannina, Donato, additional, Fabbri, Alberto, additional, Pietrantuono, Giuseppe, additional, Annibali, Ombretta, additional, Tafuri, Agostino, additional, Prete, Eleonora, additional, Mulè, Antonino, additional, Barbolini, Elisa, additional, Marcheselli, Luigi, additional, Luminari, Stefano, additional, and Merli, Francesco, additional

Published
2021
Full Text
View/download PDF

21. Prognostic Impact of Muscle Quantity and Quality and Fat Distribution in Diffuse Large B-Cell Lymphoma Patients

Author

Besutti, Giulia, primary, Massaro, Fulvio, additional, Bonelli, Efrem, additional, Braglia, Luca, additional, Casali, Massimiliano, additional, Versari, Annibale, additional, Ligabue, Guido, additional, Pattacini, Pierpaolo, additional, Cavuto, Silvio, additional, Merlo, Domenico F., additional, Luminari, Stefano, additional, Merli, Francesco, additional, Vaccaro, Salvatore, additional, and Pellegrini, Massimo, additional

Published
2021
Full Text
View/download PDF

22. Aging of bone marrow mesenchymal stromal cells: Hematopoiesis disturbances and potential role in the development of hematologic cancers

Author

Massaro, Fulvio, Corrillon, Florent, Stamatopoulos, Basile, Meuleman, Nathalie, Lagneaux, Laurence, Bron, Dominique, Massaro, Fulvio, Corrillon, Florent, Stamatopoulos, Basile, Meuleman, Nathalie, Lagneaux, Laurence, and Bron, Dominique

Abstract

Aging of bone marrow is a complex process that is involved in the development of many diseases, including hematologic cancers. The results obtained in this field of research, year after year, underline the important role of cross-talk between hematopoietic stem cells and their close environment. In bone marrow, mesenchymal stromal cells (MSCs) are a major player in cell-to-cell communication, presenting a wide range of functionalities, sometimes opposite, depending on the environmental conditions. Although these cells are actively studied for their therapeutic properties, their role in tumor progression remains unclear. One of the reasons for this is that the aging of MSCs has a direct impact on their behavior and on hematopoiesis. In addition, tumor progression is accompanied by dynamic remodeling of the bone marrow niche that may interfere with MSC functions. The present review presents the main features of MSC senescence in bone marrow and their implications in hematologic cancer progression., SCOPUS: re.j, info:eu-repo/semantics/published

Published
2021

23. Hodgkin's lymphoma: post- autologous transplantation consolidation therapy

Author

Merli, Francesco, Ballerini, Filippo, Botto, Barbara, Gotti, Manuel, Pavone, Vincenzo, Pulsoni, Alessandro, Stefani, Pietro Maria, Massaro, Fulvio, and Viviani, Simonetta

Subjects
Adult, post-autologous trasplantation, How I Treat, Hodgkin Disease, Transplantation, Autologous, Consolidation Chemotherapy, Young Adult, Humans, Female, Neoplasm Recurrence, Local, Hodgkin lymphoma, autologous stem cell transplant, consolidation therapy, Stem Cell Transplantation
Abstract

A first-line chemotherapy program based on the ABVD regimen is currently considered the golden standard by most hematologists, being able to achieve a cure without any need of subsequent therapies in >70% of patients with advanced-stage Hodgkin’s lymphoma (HL). To increase this percentage, efforts in recent decades focused on the development of new therapeutic strategies. A first major effort was the introduction of the BEACOPP chemotherapy regimen, which is able to increase the response rate and to reduce the need of salvage therapies. However, this result did not demonstrate an advantage in terms of overall survival compared to ABVD, mainly due to an excess of non lymphoma-related events in the follow-up phase. Here we describe three clinical cases of young HL patients who had relapsed/refractory disease after the induction chemotherapy. These three clinical cases provide practical and real world evidence in favor of the use of BV in monotherapy as consolidation treatment after autologous stem cells transplantation in patients with relapsed/refractory HL.

Published
2020

25. Management of Extramedullary Intradural Spinal Tumors: The Impact of Clinical Status, Intraoperative Neurophysiological Monitoring and Surgical Approach on Outcomes in a 12-Year Double-Center Experience

Author

Cofano, Fabio, primary, Giambra, Carlotta, additional, Costa, Paolo, additional, Zeppa, Pietro, additional, Bianconi, Andrea, additional, Mammi, Marco, additional, Monticelli, Matteo, additional, Di Perna, Giuseppe, additional, Junemann, Carola Vera, additional, Melcarne, Antonio, additional, Massaro, Fulvio, additional, Ducati, Alessandro, additional, Tartara, Fulvio, additional, Zenga, Francesco, additional, and Garbossa, Diego, additional

Published
2020
Full Text
View/download PDF

27. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real‐life experience.

Author

Massaro, Fulvio, Pavone, Vincenzo, Stefani, Piero Maria, Botto, Barbara, Pulsoni, Alessandro, Patti, Caterina, Cantonetti, Maria, Visentin, Andrea, Scalzulli, Potito Rosario, Rossi, Andrea, Galimberti, Sara, Cimminiello, Michele, Gini, Guido, Musso, Maurizio, Sorio, Marco, Arcari, Annalisa, Zilioli, Vittorio Ruggero, Luppi, Mario, Mannina, Donato, and Fabbri, Alberto

Subjects
STEM cell transplantation, HODGKIN'S disease, DISEASE relapse, PROGRESSION-free survival, SALVAGE therapy
Abstract

The standard management for relapsed or refractory classical Hodgkin lymphoma (cHL) is salvage therapy followed by autologous stem cell transplantation (ASCT). This strategy allows almost 50% of patients to be cured. Post‐ASCT maintenance treatment with brentuximab vedotin (BV) confers improved progression‐free survival (PFS) to cHL patients at high risk of relapse. We investigated the outcome of 105 cHL patients receiving post‐ASCT BV maintenance in the real‐life setting of 23 Italian hematology centers. This population included naïve patients and those previously exposed to BV. Median follow‐up was 20 months. Patients presented a median of two lines of treatment pre‐ASCT, with 51% receiving BV. Twenty‐nine percent of patients had at least two high‐risk factors (refractory disease, complete response [CR] less than 12 months, extranodal disease at relapse), while 16% presented none. At PET‐CT, a Deauville score (DS) of 1–3 was reported in 75% and 78% of pre‐ and post‐ASCT evaluations, respectively. Grade 3–4 adverse events (AEs), mainly peripheral neuropathy, were observed in 16% of patients. Three‐year PFS and overall survival (OS) were 62% and 86%, respectively. According to BV exposure, 3‐year PFS and OS were 54% and 71%, respectively, for naïve and 77% and 96%, respectively, for previously exposed patients. Refractory disease (hazard ratio [HR] 4.46; p = 0.003) and post‐ASCT DS 4–5 (HR 3.14; p = 0.005) were the only two factors significantly associated with PFS reduction in multivariable analysis. Post‐ASCT BV maintenance is an effective, safe treatment option for cHL naïve patients and those previously exposed to BV. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

29. Long‐term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high‐dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma

Author

Massaro, Fulvio, primary, Stepanishyna, Yana, additional, Manni, Martina, additional, Luminari, Stefano, additional, Galimberti, Sara, additional, Marcheselli, Luigi, additional, Visco, Carlo, additional, Tecchio, Cristina, additional, Stelitano, Caterina, additional, Angrilli, Francesco, additional, Petrini, Mario, additional, Merli, Francesco, additional, and Federico, Massimo, additional

Published
2020
Full Text
View/download PDF

33. Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib

Author

Cesini, Laura, primary, Carmosino, Ida, additional, Breccia, Massimo, additional, De Benedittis, Daniela, additional, Mohamed, Sara, additional, De Luca, Maria Lucia, additional, Colafigli, Gioia, additional, Molica, Matteo, additional, Scalzulli, Emilia, additional, Massaro, Fulvio, additional, Mariggiò, Elena, additional, Rizzo, Lorenzo, additional, Loglisci, Maria Giovanna, additional, Scamuffa, Maria Cristina, additional, Vozella, Federico, additional, Diverio, Daniela, additional, Mancini, Marco, additional, Alimena, Giuliana, additional, Foà, Robin, additional, and Latagliata, Roberto, additional

Published
2019
Full Text
View/download PDF

34. Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?

Author

De Benedittis, Daniela, primary, Breccia, Massimo, additional, Carmosino, Ida, additional, Mariggiò, Elena, additional, Molica, Matteo, additional, Mohamed, Sara, additional, Massaro, Fulvio, additional, De Luca, Maria Lucia, additional, Scalzulli, Emilia, additional, Lisi, Chiara, additional, Passucci, Mauro, additional, Colafigli, Gioia, additional, Loglisci, Maria Giovanna, additional, Diverio, Daniela, additional, Mancini, Marco, additional, Foà, Robin, additional, and Latagliata, Roberto, additional

Published
2018
Full Text
View/download PDF

36. Long‐term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high‐dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma.

Author

Massaro, Fulvio, Stepanishyna, Yana, Manni, Martina, Luminari, Stefano, Galimberti, Sara, Marcheselli, Luigi, Visco, Carlo, Tecchio, Cristina, Stelitano, Caterina, Angrilli, Francesco, Petrini, Mario, Merli, Francesco, and Federico, Massimo

Subjects
*RITUXIMAB, *METHOTREXATE, *CYTARABINE, *STEM cell transplantation, *LYMPHOPROLIFERATIVE disorders, *MANTLE cell lymphoma, *CASTLEMAN'S disease
Abstract

Summary: Mantle cell lymphoma is a rare and incurable lymphoproliferative disorder. In the MCL01 trial, patients were treated with the R‐HCVAD regimen [rituximab plus HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; R‐CVAD) alternating with high‐dose methotrexate and cytarabine (AM)] for four cycles followed by autologous stem cell transplantation (ASCT) for those who reached only a partial response. After a median follow‐up of 10·5 years, we reported 10‐year progression‐free and overall survival rates of 35% and 61% respectively, with a 10‐years cumulative incidence rate of second malignancies of 10·6%. Mature results of the MCL01 trial confirmed the efficacy of HyperCVAD‐AM as a frontline regimen for younger patients (≤65 years). [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

38. Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?

Author

Latagliata, Roberto, primary, Breccia, Massimo, additional, Carmosino, Ida, additional, Cesini, Laura, additional, De Benedittis, Daniela, additional, Mohamed, Sara, additional, Vozella, Federico, additional, Molica, Matteo, additional, Campanelli, Melissa, additional, De Luca, Maria Lucia, additional, Colafigli, Gioia, additional, Quattrocchi, Luisa, additional, Loglisci, Maria Giovanna, additional, Massaro, Fulvio, additional, Canichella, Martina, additional, Diverio, Daniela, additional, Mancini, Marco, additional, Alimena, Giuliana, additional, and Foà, Robin, additional

Published
2018
Full Text
View/download PDF

48. Incidence of Severe (≤ 10g/dl) Chronic Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib and Role of Erythropoietin Therapy

Author

Cesini, Laura, primary, Carmosino, Ida, additional, Campanelli, Melissa, additional, Breccia, Massimo, additional, De Luca, Maria Lucia, additional, Colafigli, Gioia, additional, Molica, Matteo, additional, Massaro, Fulvio, additional, Vozella, Federico, additional, Diverio, Daniela, additional, Mancini, Marco, additional, Alimena, Giuliana, additional, and Latagliata, Roberto, additional

Published
2016
Full Text
View/download PDF

49. Impact of Comorbidities and Body Mass Index in Myelofibrosis Patients Treated with Ruxolitinib: A Retrospective Analysis

Author

Breccia, Massimo, primary, Tiribelli, Mario, additional, Bonifacio, Massimiliano, additional, Tieghi, Alessia, additional, Polverelli, Nicola, additional, Bergamaschi, Micaela, additional, Cavazzini, Francesco, additional, Cimino, Giuseppe, additional, D'Adda, Mariella, additional, Crugnola, Monica, additional, Bosi, Costanza, additional, Spinsanti, Marco, additional, Molica, Matteo, additional, Fama, Angelo, additional, Andriani, Alessandro, additional, Cerqui, Elisa, additional, Lazzaro, Antonio, additional, Scaffidi, Luigi, additional, Massaro, Fulvio, additional, Latagliata, Roberto, additional, Celesti, Francesca, additional, Lemoli, Roberto massimo, additional, Fanin, Renato, additional, Russo, Domenico, additional, Aversa, Franco, additional, Cuneo, Antonio, additional, Cavo, Michele, additional, Vianelli, Nicola, additional, Alimena, Giuliana, additional, and Palandri, Francesca, additional

Published
2016
Full Text
View/download PDF

50. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN

Author

Breccia, Massimo, primary, Andriani, Alessandro, additional, Montanaro, Marco, additional, Abruzzese, Elisabetta, additional, Buccisano, Francesco, additional, Cedrone, Michele, additional, Centra, Antonietta, additional, Villivà, Nicoletta, additional, Celesti, Francesca, additional, Trawinska, Malgorzata Monica, additional, Massaro, Fulvio, additional, Di Veroli, Ambra, additional, Anaclerico, Barbara, additional, Colafigli, Gioia, additional, Molica, Matteo, additional, Spadea, Antonio, additional, Petriccione, Luca, additional, Cimino, Giuseppe, additional, and Latagliata, Roberto, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results